| Pt no. |
Age at Diagnosis* |
Sex |
Ethnicity |
Attack Frequency |
Current Treatment Regimen |
MGUS |
| 1 |
45 |
M |
C |
Every 4-6 weeks |
IVIG |
IgG kappa |
| 2 |
49 |
F |
C |
Weekly/monthly |
IVIG |
IgG kappa |
| 3 |
45 |
M |
C |
Every weekend |
Infliximab |
IgG kappa |
| 4 |
55 |
M |
C |
> 2/yr |
IVIG |
IgG kappa |
| 5 |
46 |
F |
C |
5-10 day intervals |
N/A (deceased) |
IgG lambda |
| 6 |
42 |
M |
C |
3-4 year intervals |
Theophylline |
IgG kappa |
| 7 |
32 |
M |
C |
3-5 year intervals |
IVIG |
IgG kappa |
| 8 |
59 |
M |
C |
Single episode |
None |
IgG kappa |
| 9 |
65 |
M |
C |
3-4/year |
IVIG |
IgG kappa |
| 10 |
39 |
F |
C |
Chronic |
T/T** |
ND# |
| 11 |
48 |
F |
C |
Infrequent |
T/T |
IgG lambda |
| 12 |
48 |
M |
C |
weekly |
IVIG |
IgG kappa |
| 13 |
50 |
F |
C |
> 2x/yr |
IVIG |
IgG kappa |
| 14 |
51 |
M |
C |
> 2x/yr |
IVIG |
IgG |
| 15 |
53 |
M |
C |
Weekly |
IVIG |
IgG lambda |
| 16 |
40 |
F |
C |
Chronic |
Theophylline |
IgG kappa |
| 17 |
43 |
F |
C |
3-4 year interval |
None |
IgG kappa |
| 18 |
64 |
F |
C |
Chronic |
Theophylline |
IgG kappa |
| 19 |
48 |
M |
AA |
3-4/yr |
IVIG |
IgG lambda |
| 20 |
43 |
M |
C |
Bimonthly |
IVIG |
IgG kappa |
| 21 |
65 |
M |
C |
Single episode |
Theophylline |
IgG kappa |
| 22 |
43 |
M |
C |
< 2x/yr |
IVIG |
IgG kappa |
| 23 |
36 |
F |
C |
< 2x/yr |
IVIG |
IgG kappa |
| 24 |
66 |
M |
C |
< 2x/yr |
IVIG |
IgG lambda |
| 25 |
40 |
F |
C |
Single episode |
IVIG |
IgG kappa |
| 26 |
62 |
M |
C |
< 2x/yr |
IVIG |
IgG kappa |
| 27 |
7 |
F |
C |
Chronic plus acute |
Subcutaneous IG |
ND# |
| 28 |
48 |
M |
C |
< 2x/yr |
IVIG |
IgG lambda |
| 29 |
61 |
M |
C |
3-4 year intervals |
IVIG |
IgG kappa |
| 30 |
43 |
F |
C |
< 2x/yr |
IVIG |
IgG lambda |
| 31 |
58 |
F |
C |
Chronic plus acute |
None |
IgM kappa |
| 32 |
33 |
M |
C |
< 2x/yr |
IVIG |
ND# |
| 33 |
37 |
F |
C |
Chronic plus acute |
IVIG |
ND# |
| 34 |
22 mo. |
F |
C |
Every 5-6 months |
|
ND# |
| 35 |
8 |
C |
C |
Weekly |
IVIG |
ND# |
| *Note: Many patients experienced episodes consistent with SCLS prior to formal diagnosis; **: Theophylline plus terbutaline; #: Not detected |
|
